Porcine Enzyme Exposure Emerges as a Plausible Route for Chronic Hepatitis E in Lung-Transplanted Cystic Fibrosis Patients
Cystic fibrosis care has long relied on porcine-derived pancreatic enzyme replacement therapy, but a new signal from Alberta raises a different concern: those capsules may also be carrying hepatitis E virus. In a regional screening study published in Gut, chronic HEV infection appeared only in cystic fibrosis lung transplant recipients, while HEV RNA was detected in a substantial fraction of independently sourced enzyme capsules. The pattern is biologically plausible and clinically important, because immunosuppression after lung transplantation can convert an otherwise self-limited zoonotic exposure into persistent viral infection.
The investigation began after an unusually high number of chronic HEV infections was recognized among people with cystic fibrosis after transplant. HEV is not commonly diagnosed in high-income countries, yet it is known to be a porcine-derived zoonosis, and genotype 3 infections can persist in immunocompromised hosts. That matters in cystic fibrosis, where pancreatic insufficiency makes lifelong enzyme therapy routine. When the same patient population also receives transplant immunosuppression, a low-level exposure can become a sustained viral problem rather than a transient laboratory abnormality.
Screening Results Separated Seropositivity From Chronic Infection
All post-transplant patients with cystic fibrosis attending the regional center were screened for HEV, and results were compared with non-transplanted people with cystic fibrosis as well as with the broader Alberta population investigated for suspected HEV between 2016 and 2022. HEV seropositivity was similar in transplanted and non-transplanted cystic fibrosis groups: 6 of 29, or 21%, versus 16 of 83, or 19%, with a p value of 0.89. On its own, that similarity could suggest background exposure rather than transplant-specific acquisition.
The picture changed when chronic infection was examined directly. Only three chronic HEV infections were identified across Alberta, and all three occurred in cystic fibrosis lung transplant recipients. Among the transplanted cystic fibrosis cohort, that translated to 3 of 29 patients, or 10.3%. In contrast, cystic fibrosis patients had a twofold higher HEV seropositivity relative risk than all other Albertans evaluated for hepatitis, and this was four times higher than the Canadian average. Those figures point to a cohort with unusually frequent exposure and unusually poor viral clearance after transplant.
A single sentence captures the clinical concern: chronic hepatitis E clustered entirely in the immunosuppressed cystic fibrosis transplant group.
Viral Sequencing Pointed Toward Porcine Genotype 3a Exposure
Genomic sequencing and phylogenetic analysis were performed in the chronic infection cases. The isolates were confirmed to be unrelated porcine-derived HEV genotype 3a, which fits the known zoonotic biology of the virus. Genotype 3a is the strain most consistent with foodborne and animal-associated transmission in industrialized settings, and its detection in this setting strengthens the argument that the infections were not random community events or a shared nosocomial outbreak.
The lack of relatedness among the cases is also informative. If the infections had clustered genetically, a common clinic-based transmission route would need to be considered. Instead, the sequencing pattern supports repeated exposure from a shared source category, which in this patient population means something consumed or used chronically rather than a one-time event.
Pancreatic Enzyme Capsules Carried Detectable HEV RNA
The most direct clue came from the product itself. Because pancreatic enzymes used in cystic fibrosis are derived from swine, independently sourced PERT capsules were screened for HEV. Ninety-one percent of the cystic fibrosis cohort was taking PERT, with a median exposure of 8,760 capsules per person per year. That is a large annual antigenic and environmental interface with porcine material, which makes contamination surveillance especially relevant.
HEV RNA was detected by RT-qPCR in 47 of 107 capsules, or 44%. Sequences from those capsules clustered with the chronic HEV cases. The finding does not prove that every contaminated capsule was infectious or that all chronic infections originated from the products tested, but it does establish a credible reservoir of viral RNA in a medication that is taken repeatedly and often for years. For transplant recipients receiving chronic immunosuppression, even intermittent viral exposure could matter if the viral load is sufficient and host clearance is impaired.
Why Lung Transplant Recipients May Be the Vulnerable Group
Immunosuppression likely explains why chronic HEV emerged only after lung transplantation. In immunocompetent hosts, HEV infection is often self-limited, and many infections go unrecognized. After transplant, T-cell suppression can prevent viral clearance and allow low-grade replication to persist. In cystic fibrosis, the same patient is also exposed to a high-volume porcine-derived medication that may contain HEV RNA, creating a repeated exposure loop. The combination of chronic ingestion plus impaired immune control is exactly the setting in which a zoonotic virus can become chronic.
This also reframes routine cystic fibrosis management. Pancreatic enzyme replacement is not optional in patients with pancreatic insufficiency; it is central to nutrition and gastrointestinal function. The question is not whether PERT should be abandoned. The question is whether product sourcing, manufacturing oversight, and targeted viral surveillance need to change for a population that is uniquely exposed and, after transplantation, uniquely vulnerable.
What the Alberta Cohort Does and Does Not Prove
The data support a strong association between cystic fibrosis lung transplantation, chronic HEV, and porcine enzyme exposure. They do not prove causality. The study did not show the exact infectious dose delivered by each contaminated capsule, and it did not establish that all HEV-positive capsules were capable of initiating human infection. The cohort was also regional, which limits how far the findings can be generalized without confirmation from other centers and other jurisdictions.
Even with those limits, the signal is difficult to ignore. HEV seropositivity was elevated in people with cystic fibrosis, chronic infection appeared only after lung transplantation, and HEV RNA was detectable in nearly half of the tested enzyme capsules, with sequence clustering between the capsules and the patient isolates. For clinicians caring for lung-transplanted cystic fibrosis patients, unexplained hepatitis should now prompt consideration of hepatitis E virus, not just the usual medication toxicity or biliary causes.
Future work needs to define incidence and prevalence in larger cystic fibrosis cohorts, measure the risk across different PERT sources, and determine whether routine screening should be built into transplant follow-up. The practical consequence is immediate: chronic HEV should be on the differential when a cystic fibrosis transplant recipient develops persistent liver enzyme abnormalities, especially if porcine enzyme therapy is part of daily care.